EP3464339A4 - Dosage protéolytique du peptide natriurétique de type b pour l'évaluation du risque de maladie cardiovasculaire - Google Patents

Dosage protéolytique du peptide natriurétique de type b pour l'évaluation du risque de maladie cardiovasculaire Download PDF

Info

Publication number
EP3464339A4
EP3464339A4 EP17807518.0A EP17807518A EP3464339A4 EP 3464339 A4 EP3464339 A4 EP 3464339A4 EP 17807518 A EP17807518 A EP 17807518A EP 3464339 A4 EP3464339 A4 EP 3464339A4
Authority
EP
European Patent Office
Prior art keywords
cardiovascular disease
risk assessment
natriuretic peptide
disease risk
type natriuretic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17807518.0A
Other languages
German (de)
English (en)
Other versions
EP3464339A1 (fr
Inventor
Shenyan ZHANG
Koen RAEDSCHELDERS
Jennifer Van Eyk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of EP3464339A1 publication Critical patent/EP3464339A1/fr
Publication of EP3464339A4 publication Critical patent/EP3464339A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/326—Arrhythmias, e.g. ventricular fibrillation, tachycardia, atrioventricular block, torsade de pointes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP17807518.0A 2016-06-03 2017-06-01 Dosage protéolytique du peptide natriurétique de type b pour l'évaluation du risque de maladie cardiovasculaire Withdrawn EP3464339A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662345595P 2016-06-03 2016-06-03
PCT/US2017/035544 WO2017210488A1 (fr) 2016-06-03 2017-06-01 Dosage protéolytique du peptide natriurétique de type b pour l'évaluation du risque de maladie cardiovasculaire

Publications (2)

Publication Number Publication Date
EP3464339A1 EP3464339A1 (fr) 2019-04-10
EP3464339A4 true EP3464339A4 (fr) 2019-12-25

Family

ID=60477940

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17807518.0A Withdrawn EP3464339A4 (fr) 2016-06-03 2017-06-01 Dosage protéolytique du peptide natriurétique de type b pour l'évaluation du risque de maladie cardiovasculaire

Country Status (2)

Country Link
EP (1) EP3464339A4 (fr)
WO (1) WO2017210488A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11193947B2 (en) 2016-06-03 2021-12-07 Cedars-Sinai Medical Center B-type natriuretic peptide proteolytic assay for cardiovascular disease risk assessment
JP7219530B2 (ja) * 2017-12-28 2023-02-08 塩野義製薬株式会社 Ｂｎｐ測定用標準品

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008030901A2 (fr) * 2006-09-07 2008-03-13 Abbott Laboratories Fragments de biomarqueurs pour la détection du bnp humain

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1557431B1 (fr) * 1996-03-04 2012-08-15 Scios Inc. Analyses et réactifs permettant de quantifier le hbnp
AUPS169202A0 (en) * 2002-04-11 2002-05-16 Goetze, Jens Peter Neuropeptide assay
EP1722232A1 (fr) * 2005-05-09 2006-11-15 F.Hoffmann-La Roche Ag Dispositifs et procédés de diagnostics ou de prévoir d'un stade précoce des dysfonctionnements cardiaques
EP2294079A2 (fr) * 2008-05-16 2011-03-16 Pronota NV Nouveaux polypeptides apparentés à des peptides natriurétiques de type b et leurs procédés d'identification et d'utilisation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008030901A2 (fr) * 2006-09-07 2008-03-13 Abbott Laboratories Fragments de biomarqueurs pour la détection du bnp humain

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
J. Y. Y. FOO ET AL: "Circulating Fragments of N-Terminal Pro-B-Type Natriuretic Peptides in Plasma of Heart Failure Patients", CLINICAL CHEMISTRY, vol. 59, no. 10, 1 October 2013 (2013-10-01), pages 1523 - 1531, XP055368001, ISSN: 0009-9147, DOI: 10.1373/clinchem.2012.200204 *
See also references of WO2017210488A1 *
SHENYAN ZHANG ET AL: "Profiling B-Type Natriuretic Peptide Cleavage Peptidoforms in Human Plasma by Capillary Electrophoresis with Electrospray Ionization Mass Spectrometry", JOURNAL OF PROTEOME RESEARCH, vol. 16, no. 12, 1 September 2017 (2017-09-01), pages 4515 - 4522, XP055641736, ISSN: 1535-3893, DOI: 10.1021/acs.jproteome.7b00482 *
ZHANG SAN-MING ET AL: "Association between serum corin levels and risk of acute myocardial infarction", CLINICA CHIMICA ACTA, ELSEVIER BV, AMSTERDAM, NL, vol. 452, 11 November 2015 (2015-11-11), pages 134 - 137, XP029365998, ISSN: 0009-8981, DOI: 10.1016/J.CCA.2015.11.012 *

Also Published As

Publication number Publication date
WO2017210488A1 (fr) 2017-12-07
EP3464339A1 (fr) 2019-04-10

Similar Documents

Publication Publication Date Title
EP3636761A4 (fr) Protéine de liaison à l'antigène reconnaissant un peptide dérivé d'un mage-a4
IL275298A (en) Mitochondria-targeted peptides
EP3341395A4 (fr) Protéine recombinante (icp)-socs3 perméable dans les cellules améliorée et ses utilisations
EP3328429A4 (fr) Peptides et anticorps pour l'élimination de biofilms
IL251571B (en) Variable proteins comprising the cry1da1 amino acid sequence are activated by lepidopteran
HK1254601A1 (zh) 新型肽
EP3191629A4 (fr) Microréseaux de peptides et nouveaux biomarqueurs pour la maladie c liaque
SG11202005653RA (en) Novel peptide
EP3120147A4 (fr) Dosage de protéines glyquées
GB201607534D0 (en) Peptides
EP3231867A4 (fr) Peptide d'antigène tumoral
SG10201913521TA (en) Methods for enzymatic peptide ligation
EP3330376A4 (fr) ANTICORPS ANTI-PROTÉINE Eva1
EP3464339A4 (fr) Dosage protéolytique du peptide natriurétique de type b pour l'évaluation du risque de maladie cardiovasculaire
GB201604468D0 (en) Peptides
EP3653063A4 (fr) Peptide
EP3424943A4 (fr) Peptide
EP3725884A4 (fr) Peptide pouvant traverser la membrane cellulaire
EP3464377A4 (fr) Peptides dérivés de dsg2
IL250003A0 (en) You will notice srm/mrm for the kras gtpase protein
GB201612150D0 (en) Modified peptide
GB201607535D0 (en) Peptides
IS3008B (is) Stöðgandi lausnir fyrir prótín og peptíð
GB201719520D0 (en) Neuroprotectvie peptide
GB201715379D0 (en) Peptides

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20181214

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20191126

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/58 20060101AFI20191120BHEP

Ipc: G01N 33/74 20060101ALI20191120BHEP

Ipc: G01N 33/68 20060101ALI20191120BHEP

Ipc: G01N 33/573 20060101ALI20191120BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200911

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20210122